Though we have seen great progress in treating eye disease over the past decade with significant advancements for age-related macular degeneration, glaucoma and diabetic macular edema, there is still more to do for those suffering from dry eye disease, uveitis and many other conditions. That’s why we are committed to the advancement of eye health through both biopharmaceutical and medical device and diagnostic development.
Chiltern has a team of medical professionals who are leaders in their fields with dozens of years of experience — adding support and value to your project with their expertise and leadership. Working as a cross-functional group, the team collaborates with you to provide ophthalmological advice from medical, operational, regulatory and cost-efficiency perspectives. The relationships they foster with key opinion leaders, their understanding of imaging technologies, and our current partnerships with reading centers and other ophthalmic vendors allow them to provide deeper insights and strategic guidance, leading to better patient experiences, improved clinical outcomes and expedited regulatory approvals. Chiltern’s ophthalmology experience includes a wide variety of approaches, including, drugs, monoclonal antibodies, device, combination products, injections, drops, gene therapy and cell therapy.
Over the past five years, Chiltern has conducted 106 ophthalmology studies.
Ophthamology Bio and Med Device
Top Ophthalmology Indications From the Past Five Years
- Diabetic macular edema
- Dry eye
- Eyelash hypotrichosis
- Macular degeneration
- Macular edema
- Optic neuropathy
- Retinal detachment
- Vitreomacular adhesion